Iovance Biotherapeutics announced the FDA’s Biologics License Application for lifileucel will likely be completed in Q1 of 2023, a short delay after the agency requested additional data.
https://www.pharmalive.com/wp-content/uploads/2021/05/Iovance-Biotherapeutics-Faces-Another-Delay-in-BLA-Submission-for-TIL-Therapy-BioSpace-5-19-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-11-18 10:38:212022-11-18 10:38:21Iovance’s BLA for advanced melanoma therapeutic delayed until Q1 2023
